Bristol-Myers Squibb Company (NYSE: BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...

Princeton, New Jersey Wednesday, January 14, 2026, 12:00 Hrs [IST] ...

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed (R) , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO (TM) (aficamten), indicated ...

CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive ...

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...

Background: The convalescent phase of myocarditis in patients with preserved left ventricular ejection fraction remains poorly characterized. Persistent myocardial inflammation may elevate the risk of ...

Background Non-dilated left ventricular cardiomyopathy (NDLVC), characterised by non-ischaemic scar/fatty replacement or isolated systolic dysfunction without dilatation, lacks validated risk ...

Outflow tract ventricular arrhythmias (OT-VAs) are the most common type of idiopathic VAs.1 Despite their often benign clinical presentation, patients may experience symptoms that may severely impact ...

What is double inlet left ventricle? Double inlet left ventricle is a type of single ventricle congenital heart defect, meaning only one of the heart’s two pumping chambers (called a ventricle) is ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Myqorzo is a cardiac myosin ...